Key facts
At a glance
The numbers you need before deciding.
Weight loss
14.9–16.6%
Monthly cost
$349–$399/mo
How you take it
Weekly injection or daily pill
Main side effect
Nausea
Fat vs lean
79% fat
If you stop
~12% regain
Before you start
Learn about this treatment
Everything you'd want to know before deciding.
On treatment
Already taking this?
Practical guides for people currently on this medication.
Compare
Side-by-side comparisons
See how this drug compares with another, side by side.
Clinical evidence
How it compares in trials
Average weight loss % — from individual phase 3 trials
Body composition and what happens after stopping
What does the lost weight consist of?
Resistance training (weight lifting, bodyweight exercises) can significantly reduce the muscle loss. Aim for 2–3 sessions per week during weight loss.
Source: STEP 1 body scan analysis
What happens when you stop
Source: STEP 1 extension — Wilding et al. Diabetes Obes Metab 2022
medication
after stopping
after 1 year
In studies, people regained about 68% of the weight they lost within a year of stopping — ending about 5.6% below their starting weight. This is the body returning to its defended weight — not a personal failure. Current evidence supports long-term use for people who respond well.
Is this right for you?
Who this tends to fit
Relevant if you
- Want a proven GLP-1 drug with proven heart benefits
- Want the choice between injection and a lower-cost pill ($149–$299/month)
- BMI 30+ or 27+ with health conditions
- Prefer a well-established weight loss medication with a long trial record
Not right if you
- You have a personal or family history of medullary thyroid cancer
- You have a history of pancreatitis
- You are pregnant or planning to become pregnant
- You want more weight loss than semaglutide's own trials have shown
Safety
Important cautions
- In animal studies, semaglutide caused thyroid tumours. It is unknown whether this applies to humans, but it is not prescribed to people with a personal or family history of medullary thyroid cancer.
- Stop taking and contact your doctor immediately if you have persistent severe abdominal pain — this may be a sign of pancreatitis.
- This drug may increase the risk of gallbladder problems, including gallstones. Tell your doctor if you develop sudden upper abdominal pain.
Read the boxed warning explained in full. See what the label says about pregnancy and breastfeeding. Availability varies by pharmacy — check current shortage status.
Practical guide
How to take Wegovy & Ozempic
Available as a weekly injection (Wegovy 2.4mg) or a daily pill (Wegovy 25mg)
Injection: inject under the skin of your thigh, abdomen, or upper arm once per week. Store in the refrigerator.
Pill: take on an empty stomach with no more than 4 oz of plain water. Wait at least 30 minutes before eating, drinking, or taking other medications.
You start at a low dose and your doctor gradually increases it over about 4–5 months so your body can adjust
Common questions
FAQ
For the full regain timeline, week by week, see what the trials found after stopping.
Questions to ask your doctor
- →Am I a good candidate given my health history and any other conditions I have?
- →Do I have any contraindications I should know about?
- →What results should I realistically expect, and over what timeframe?
- →Which side effects should make me contact you?
- →How long should I try this before we decide if it's working?
- →What happens if I need to stop — how do I come off it safely?
Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice
Sources & references
- [1]STEP 11,961 adults with obesity or overweight with comorbidities, no type 2 diabetes · 68 weeks14.9% mean weight loss. 86% achieved ≥5% loss; 69% achieved ≥10%; 50% achieved ≥15%. Nausea 44% vs. 16% placebo; diarrhoea 30% vs. 16%; vomiting 24% vs. 6%; constipation 24% vs. 11%.New England Journal of Medicine (2021) ↗
- [2]STEP 2Adults with obesity and type 2 diabetes · 68 weeks9.6% mean weight loss — lower than STEP 1 because type 2 diabetes reduces GLP-1 response. Significant HbA1c improvements.New England Journal of Medicine (2021) ↗
- [3]STEP 5Adults with obesity or overweight with comorbidities, no type 2 diabetes · 104 weeks (2 years)15.2% sustained mean weight loss at 2 years — showing durable effect with continued use.Nature Medicine (2022) ↗
- [4]OASIS 4 (oral semaglutide 25mg)307 adults with obesity or overweight + ≥1 comorbidity · 64 weeks13.6% average weight loss (all participants, including those who reduced dose or stopped). 16.6% average weight loss with full adherence. 76.3% achieved ≥5% weight loss vs. 31.3% placebo. About 1 in 3 adherent participants achieved ≥20% weight loss.New England Journal of Medicine (2024) ↗
- [5]SELECT (cardiovascular outcomes)17,604 adults with established cardiovascular disease and overweight or obesity (BMI 27 or higher), without type 2 diabetes · ~40 months (median)20% reduction in MACE (non-fatal heart attack, non-fatal stroke, or cardiovascular death) vs. placebo — the first weight loss drug to demonstrate CV event reduction.New England Journal of Medicine (2023) ↗
- [6]Wegovy (semaglutide) tablets — FDA prescribing informationOral semaglutide 25mg tablet-treated patients vs. placebo, OASIS 4 trial population · 68 weeks6.9% of tablet-treated patients discontinued treatment due to adverse reactions, vs. 5.9% with placebo (section 6.1, adverse reactions).FDA prescribing information (DailyMed) (2025) ↗